GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » Shiller PE Ratio

Zealand Pharma A/S (OCSE:ZEAL) Shiller PE Ratio : (As of May. 03, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma A/S Shiller PE Ratio Historical Data

The historical data trend for Zealand Pharma A/S's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Shiller PE Ratio Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zealand Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zealand Pharma A/S's Shiller PE Ratio

For the Biotechnology subindustry, Zealand Pharma A/S's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Shiller PE Ratio falls into.



Zealand Pharma A/S Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zealand Pharma A/S's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Zealand Pharma A/S's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-4.6/116.7000*116.7000
=-4.600

Current CPI (Dec. 2023) = 116.7000.

Zealand Pharma A/S Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 1.130 99.600 1.324
201406 -2.110 99.700 -2.470
201409 0.740 99.700 0.866
201412 -2.780 99.400 -3.264
201503 -2.450 100.200 -2.853
201506 -3.400 100.300 -3.956
201509 -2.210 100.200 -2.574
201512 3.050 99.800 3.566
201603 -3.270 100.200 -3.808
201606 -4.100 100.600 -4.756
201609 -1.290 100.200 -1.502
201612 2.180 100.300 2.536
201703 -1.030 101.200 -1.188
201706 -3.690 101.200 -4.255
201709 -1.510 101.800 -1.731
201712 -3.630 101.300 -4.182
201803 -3.170 101.700 -3.638
201806 -3.590 102.300 -4.095
201809 29.960 102.400 34.144
201812 -4.250 102.100 -4.858
201903 -4.130 102.900 -4.684
201906 -4.333 102.900 -4.914
201909 -3.440 102.900 -3.901
201912 -5.420 102.900 -6.147
202003 -4.980 103.300 -5.626
202006 -1.570 103.200 -1.775
202009 -5.760 103.500 -6.495
202012 -9.680 103.400 -10.925
202103 -5.780 104.300 -6.467
202106 -6.870 105.000 -7.636
202109 -4.610 105.800 -5.085
202112 -6.490 106.600 -7.105
202203 -5.160 109.900 -5.479
202206 -11.040 113.600 -11.341
202209 -3.210 116.400 -3.218
202212 -6.740 115.900 -6.787
202303 -3.760 117.300 -3.741
202306 -5.500 116.400 -5.514
202309 1.230 117.400 1.223
202312 -4.600 116.700 -4.600

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zealand Pharma A/S  (OCSE:ZEAL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Zealand Pharma A/S Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (OCSE:ZEAL) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.